Daekwon Kim / CEO, R&D

Korea Health Industry Development Institute
Seoul National University, Pharmacy, M.S.
Seoul National University, Pharmacy, B.S.

Hyuntai Kim / CEO, Management

Seoul National University Business School, MBA
Seoul National University Business School, B.A.

Younkyoung Lee / Clinical Development

Boehringer Ingelheim Korea, Clinical Development Director
Seoul National University, Public Health, M.S.
Seoul National University, Nursing, B.S.

Dr. Sunghwan Kim /  Biochemistry

Polus, Development Director
Catholic University, Research Professor
Massachusetts Institute of Technology(MIT), Post Doc

Sangjin Woo / Finance

Seoul National University Business School, MBA
Seoul National University Business School, B.A.

Ikhwan Sung / Operations

McKinsey & Co. / The Rohatyn Group
Wharton School, MBA
Seoul National University Business School, B.A.

Sangjin Lee / Human Resources

Bank of Korea
Seoul National University, Economics, B.A.

Jaeyoung Ahn / Business Development(Advanced markets)

UC Berkeley, MFE
Seoul National University, Engineering, B.S.

Junil Park / Business Development(China and Emerging markets)

Mirae Asset, PEF
Peking University, B.A.

Giho Kwon / Legal Affairs

46th Judicial Examination
Seoul National University, Law, LL.M.
Seoul National University, Law, LL.B.

Noori Seo / External Relations

Sungkyunkwan University Law School, LL.M.
Seoul National University, Politics, B.A.

Lim Jaeyoung / Intellectual Property

Patent attorney
KIM&CHANG
Seoul National University, B.S.

Hyunseok Kim / Artificial Intelligence

Hongik University, Adjunct Professor
Yonsei University, Engineering, M.S.

Dr.Namdoo Kim / CEO of Voronoi Bio

National New Drug Development Center
Yonsei University, Ph.D.

Dr. Jungbeom Son / CTO of Voronoi Bio

Sogang University, Ph.D.

Dr. Hwangeun Choi / CEO of B2S Bio

“Small-Molecule Inhibitors of LRRK2”(2017), Advances in Neurobiology vol. 14, Co-author
Dana Farber Cancer Institute, Staff Scientist

Dr. Nathanael Gray /  Co-Founder of B2S Bio

Professor at Harvard Medical School(Dana Farber Cancer Institute)
Genomics Institute of the Novartis Research Foundation Kinase Inhibitor Group Leader

Dr. Eunhwa Ko / CTO of B2S Bio

Yale University, Post Doc
Texas A&M University, Ph.D.